{
    "nct_id": "NCT06233461",
    "official_title": "A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "1. Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is >=19 years of age.\n2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.\n3. Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for CD.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis.\n2. Have complications of CD that might require surgery during the study.\n3. Participants with a current ostomy.\n4. Participants who have failed 3 or more classes of advanced therapies.",
    "miscellaneous_criteria": ""
}